Susan Blum

September 1, 2022

Susan joined Melinta Therapeutics in 2016 and was an integral part of Melinta’s leadership team, serving as CFO from April 2021 until August 2025, at which time she assumed the role of CFO for CorMedix in connection with the merger of the companies. With more than 25 years of experience in both public and private companies, Susan brings deep experience in strategic planning, risk management, and financial operations.  Before joining Melinta, she served in leadership positions within corporate controllership and financial reporting at Textura Corporation (now Oracle), Orbitz Worldwide (now Expedia), and PDL BioPharma and Facet Therapeutics (now Abbott), in which she played key roles in public offerings, mergers, acquisitions, and other strategic transactions. In April 2024, Susan was appointed to the Board of Directors and Audit Committee Chair for BiomX, a public, clinical-stage company pioneering phage cocktails to combat bacteria in chronic diseases. She holds a B.S. in Business Commerce, concentration in Accounting, from Santa Clara University and is a certified public accountant.